metizoline: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 28688 |
| CHEMBL ID | 1370446 |
| CHEBI ID | 136017 |
| SCHEMBL ID | 249827 |
| MeSH ID | M0055597 |
| Synonym |
|---|
| LOPAC0_000192 |
| NCGC00015152-01 |
| lopac-b-4555 |
| benazoline oxalate |
| NCGC00162086-01 |
| CHEBI:136017 |
| metizoline |
| NCGC00015152-03 |
| metyzoline |
| 2-[(2-methyl-1-benzothiophen-3-yl)methyl]-4,5-dihydro-1h-imidazole |
| metizolinum [inn-latin] |
| metizolinum |
| z27l8n105u , |
| metizolina |
| unii-z27l8n105u |
| 1h-imidazole, 4,5-dihydro-2-((2-methylbenzo(b)thien-3-yl)methyl)- |
| 17692-22-7 |
| metizoline [inn:ban] |
| metizolina [inn-spanish] |
| CCG-204287 |
| CHEMBL1370446 |
| NCGC00015152-02 |
| 1h-imidazole, 4,5-dihydro-2-[(2-methylbenzo[b]thien-3-yl)methyl]- |
| metizoline [inn] |
| metizoline [who-dd] |
| 2-((2-methylbenzo(b)thien-3-yl)methyl)-2-imidazoline |
| metizoline [mi] |
| SCHEMBL249827 |
| DTXSID9074983 |
| DB13614 |
| Q6824158 |
| SDCCGSBI-0050180.P002 |
| NCGC00015152-04 |
| Class | Description |
|---|---|
| 1-benzothiophenes | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 20.4839 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 20.4839 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 28.4258 | 0.1000 | 20.8793 | 79.4328 | AID488772; AID588453; AID588456 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 0.0447 | 0.0282 | 7.0559 | 15.8489 | AID895; AID928 |
| GLS protein | Homo sapiens (human) | Potency | 5.6234 | 0.3548 | 7.9355 | 39.8107 | AID624146 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 0.2512 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 11.2202 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0020 | 7.5337 | 39.8107 | AID891 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 6.0297 | 0.0224 | 5.9449 | 22.3872 | AID488982; AID488983 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID488953 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 8.4368 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| Ataxin-2 | Homo sapiens (human) | Potency | 39.8107 | 0.0119 | 12.2221 | 68.7989 | AID588378 |
| 2,3-bisphosphoglycerate-independent phosphoglycerate mutase | Leishmania major strain Friedlin | Potency | 33.8078 | 7.5686 | 15.2306 | 21.3313 | AID504548 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| negative regulation of receptor internalization | Ataxin-2 | Homo sapiens (human) |
| regulation of translation | Ataxin-2 | Homo sapiens (human) |
| RNA metabolic process | Ataxin-2 | Homo sapiens (human) |
| P-body assembly | Ataxin-2 | Homo sapiens (human) |
| stress granule assembly | Ataxin-2 | Homo sapiens (human) |
| RNA transport | Ataxin-2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| RNA binding | Ataxin-2 | Homo sapiens (human) |
| epidermal growth factor receptor binding | Ataxin-2 | Homo sapiens (human) |
| protein binding | Ataxin-2 | Homo sapiens (human) |
| mRNA binding | Ataxin-2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytoplasm | Ataxin-2 | Homo sapiens (human) |
| Golgi apparatus | Ataxin-2 | Homo sapiens (human) |
| trans-Golgi network | Ataxin-2 | Homo sapiens (human) |
| cytosol | Ataxin-2 | Homo sapiens (human) |
| cytoplasmic stress granule | Ataxin-2 | Homo sapiens (human) |
| membrane | Ataxin-2 | Homo sapiens (human) |
| perinuclear region of cytoplasm | Ataxin-2 | Homo sapiens (human) |
| ribonucleoprotein complex | Ataxin-2 | Homo sapiens (human) |
| cytoplasmic stress granule | Ataxin-2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347050 | Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1347059 | CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347410 | qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library | 2019 | Cellular signalling, 08, Volume: 60 | A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID588349 | qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay | |||
| AID1347057 | CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID588378 | qHTS for Inhibitors of ATXN expression: Validation | |||
| AID1347405 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID504836 | Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation | 2002 | The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16 | Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. |
| AID1347058 | CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347151 | Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347045 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347049 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 5 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.12) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (5.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 19 (95.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||